APA (7th ed.) Citation

Jia, X., Wang, K., Zhuo, Q., Zhao, Z., & Li, M. (2024). PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety. Clinical Breast Cancer, 24(5), 392-398. https://doi.org/10.1016/j.clbc.2024.02.020

Chicago Style (17th ed.) Citation

Jia, Xiaomeng, Kainan Wang, Qiping Zhuo, Zuowei Zhao, and Man Li. "PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety." Clinical Breast Cancer 24, no. 5 (2024): 392-398. https://doi.org/10.1016/j.clbc.2024.02.020.

MLA (8th ed.) Citation

Jia, Xiaomeng, et al. "PARP Inhibitor for Neoadjuvant Therapy in HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety." Clinical Breast Cancer, vol. 24, no. 5, 2024, pp. 392-398, https://doi.org/10.1016/j.clbc.2024.02.020.

Warning: These citations may not always be 100% accurate.
Visit our Citation Styles guide for help on properly citing sources.